CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,007 enrolled
Drug / intervention
MRIprocedure
Likely dose
Not stated in record
Key inclusion· 5
  • Recently confirmed unilateral ductal carcinoma in situ or invasive breast cancer, confirmed by biopsy or FNA within past 60 days
  • Negative or benign mammogram (BI-RADS 1 or 2) and negative/benign clinical breast exam of contralateral breast within past 90 days
  • Age 18 years or older
  • Female sex
Key exclusion· 8
  • Remote history of breast cancer
  • New breast symptoms within past 60 days for which further evaluation is recommended
  • Pacemaker or magnetic aneurysm clips
  • Implanted magnetic device

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00058058
NCT00058058N/ACompleted

MRI Evaluation Of The Contralateral Breast In Women With Recent Diagnosis Of Breast Cancer

American College of Radiology Imaging Network·interventional·Posted Apr 9, 2003·Updated Jul 16, 2019

In Brief

A clinical study evaluating MRI for Breast Cancer and Contralateral Breast Cancer. Completed, enrolled 1,007 participants across 21 sites in 3 countries.

Detailed Summary

RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may improve the ability to detect cancer in the unaffected breast of women recently diagnosed with unilateral breast cancer. PURPOSE: Diagnostic trial to determine the effectiveness of MRI in evaluating the unaffected breast of women recently diagnosed with unilateral breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Germany, United States

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2003
Enrollment StartFeb 1, 2003
Primary CompletionAug 8, 2006
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 23.2 years ago

Interventions

MRIprocedure

Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.